We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will UnitedHealth's Push for Access to Trump Calm Investor Jitters?
Read MoreHide Full Article
Key Takeaways
Leadership met with DOJ and White House officials to discuss policy and investigations.
UnitedHealth lost 30.3% year to date, underperforming the industry.
UNH trades at 20.65X forward earnings, with 2025 EPS estimate down 41.4% year over year.
UnitedHealth Group Incorporated (UNH - Free Report) , facing criminal and civil investigations into its Medicare Advantage business and financial pressure from new federal billing rules, has stepped up the lobbying efforts in Washington, per the Wall Street Journal. The company has almost doubled its lobbying budget this year so far, hiring lawyers and lobbyists closer to President Trump’s administration officials.
Its leadership reportedly held high-level meetings with Justice Department and White House officials to discuss policy, billing and ongoing probes. UnitedHealth also changed its legal team, bringing in attorneys with closer ties to President Trump. These moves reflect UNH’s efforts to manage regulatory risks, protect its Medicare Advantage revenues and stabilize investor confidence.
According to the WSJ, the company is seeking a meeting with President Trump, though discussions have not yet been finalized. The outreach comes as the administration advances its “most favored nation” policy, designed to reduce drug prices and enhance market transparency.
UnitedHealth, the industry’s largest insurer, remains a key player given its scale and influence. The company is currently in the turnaround phase with CEO Stephen Hemsley back on the helm. Investor confidence has been reinforced by Warren Buffett’s Berkshire Hathaway Inc.’s (BRK.B - Free Report) purchase of more than 5 million shares in the second quarter, representing an investment of around $1.57 billion.
The Journal also highlighted a slight uptick in lobbying spending at both Humana Inc. (HUM - Free Report) and The Cigna Group (CI - Free Report) . Market concerns around Medicare Advantage remain elevated, particularly following reports that higher “cut point” thresholds may challenge Humana’s ability to achieve quality bonus payments. Shares of Humana moved lower on the news, reflecting investor caution.
Cigna, by contrast, has strategically scaled back its Medicare Advantage presence through selective divestitures. Management is redirecting focus toward health services and commercial insurance, segments that carry lower regulatory complexity and more favorable margin dynamics. This repositioning is expected to enhance profitability and expand Cigna’s presence in less volatile areas of the healthcare market.
UnitedHealth’s Price Performance, Valuation and Estimates
Thanks to recent jumps in share price, UNH’s year-to-date decline was reduced to 30.3%. The industry declined 24.3% during this time.
Image Source: Zacks Investment Research
From a valuation standpoint, UnitedHealth trades at a forward price-to-earnings ratio of 20.65, up from the industry average of 16.36. UNH carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for UnitedHealth’s 2025 earnings is pegged at $16.21 per share, implying a 41.4% drop from the year-ago period.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #5 (Strong Sell).
Image: Bigstock
Will UnitedHealth's Push for Access to Trump Calm Investor Jitters?
Key Takeaways
UnitedHealth Group Incorporated (UNH - Free Report) , facing criminal and civil investigations into its Medicare Advantage business and financial pressure from new federal billing rules, has stepped up the lobbying efforts in Washington, per the Wall Street Journal. The company has almost doubled its lobbying budget this year so far, hiring lawyers and lobbyists closer to President Trump’s administration officials.
Its leadership reportedly held high-level meetings with Justice Department and White House officials to discuss policy, billing and ongoing probes. UnitedHealth also changed its legal team, bringing in attorneys with closer ties to President Trump. These moves reflect UNH’s efforts to manage regulatory risks, protect its Medicare Advantage revenues and stabilize investor confidence.
According to the WSJ, the company is seeking a meeting with President Trump, though discussions have not yet been finalized. The outreach comes as the administration advances its “most favored nation” policy, designed to reduce drug prices and enhance market transparency.
UnitedHealth, the industry’s largest insurer, remains a key player given its scale and influence. The company is currently in the turnaround phase with CEO Stephen Hemsley back on the helm. Investor confidence has been reinforced by Warren Buffett’s Berkshire Hathaway Inc.’s (BRK.B - Free Report) purchase of more than 5 million shares in the second quarter, representing an investment of around $1.57 billion.
The Journal also highlighted a slight uptick in lobbying spending at both Humana Inc. (HUM - Free Report) and The Cigna Group (CI - Free Report) . Market concerns around Medicare Advantage remain elevated, particularly following reports that higher “cut point” thresholds may challenge Humana’s ability to achieve quality bonus payments. Shares of Humana moved lower on the news, reflecting investor caution.
Cigna, by contrast, has strategically scaled back its Medicare Advantage presence through selective divestitures. Management is redirecting focus toward health services and commercial insurance, segments that carry lower regulatory complexity and more favorable margin dynamics. This repositioning is expected to enhance profitability and expand Cigna’s presence in less volatile areas of the healthcare market.
UnitedHealth’s Price Performance, Valuation and Estimates
Thanks to recent jumps in share price, UNH’s year-to-date decline was reduced to 30.3%. The industry declined 24.3% during this time.
From a valuation standpoint, UnitedHealth trades at a forward price-to-earnings ratio of 20.65, up from the industry average of 16.36. UNH carries a Value Score of C.
The Zacks Consensus Estimate for UnitedHealth’s 2025 earnings is pegged at $16.21 per share, implying a 41.4% drop from the year-ago period.
The stock currently carries a Zacks Rank #5 (Strong Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.